Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential including in breast cancer and other solid tumors..

吉利德科学公司（NASDAQ: GILD）和凯米拉治疗公司（NASDAQ: KYMR）今天宣布，他们已达成一项独家选择权和许可协议，以加速开发和商业化一种新型分子胶降解剂（MGD）项目，该降解剂靶向细胞周期蛋白依赖性激酶2（CDK2），在乳腺癌和其他实体瘤等广泛肿瘤治疗领域具有潜在应用价值。

CDK2-directed MGDs are a new type of drug designed to remove CDK2 – a key contributor in tumor growth – rather than just inhibiting its function. Traditional inhibitors of CDK2 prevent it from working but often interfere with similar proteins, which can cause undesired side effects. MGDs have the potential to provide more precise, safe and effective treatments for cancers that rely on CDK2 activity by selectively removing this protein from cells..

CDK2导向的MGDs是一种新型药物，旨在去除CDK2——肿瘤生长的关键因素——而不是仅仅抑制其功能。传统的CDK2抑制剂阻止其发挥作用，但往往会干扰相似的蛋白质，可能引发不良副作用。MGDs有潜力通过选择性地从细胞中移除该蛋白，为依赖CDK2活性的癌症提供更精准、安全和有效的治疗。

“MGDs are opening exciting new possibilities in cancer research by offering a way to eliminate disease-driving proteins rather than just blocking them. This mechanism aligns within our oncology scientific framework where we evaluate therapeutic agents that selectively target and kill cancer cells with minimal impact on healthy tissue,” said Flavius Martin, MD, Executive Vice President, Research, Gilead Sciences.

“MGDs 通过提供一种消除致病蛋白而不仅仅是阻断它们的方法，为癌症研究开辟了令人兴奋的新可能性。这种机制符合我们的肿瘤学科学框架，即评估选择性靶向并杀死癌细胞且对健康组织影响最小的治疗药物，”吉利德科学公司执行副总裁、研究主管弗拉维乌斯·马丁医学博士表示。

“We are delighted to partner with Kymera to advance this novel oral program with the potential to drive meaningful improvements in the standard of care for patients living with breast cancer and other cancers that are inadequately served with existing therapies.”.

“我们很高兴与Kymera合作，推进这一具有潜力的新型口服项目，有望为乳腺癌及其他目前现有疗法未能充分满足需求的癌症患者带来有意义的治疗标准改进。”

“We are excited to announce this strategic collaboration with Gilead Sciences, highlighting our dedication to innovation in the field with our first disclosed molecular glue program. We are committed to developing highly selective, potent, oral degrader medicines that address key disease-causing proteins and pathways that are undrugged or inadequately drugged by existing technologies,” said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics.

“我们很高兴宣布与吉利德科学达成这项战略合作，突显了我们在该领域的创新承诺以及我们首次公开的分子胶项目。我们致力于开发高度选择性、强效的口服降解药物，针对现有技术未能解决或未充分解决的关键致病蛋白和通路，”Kymera Therapeutics创始人、总裁兼首席执行官Nello Mainolfi博士说道。

“Our highly specific, orally active, CDK2 molecular glue degraders have demonstrated a compelling preclinical profile and have the potential to transform the therapeutic landscape for breast cancer patients and other tumor types with high unmet medical need. We are excited to work with the talented Gilead team to accelerate the development and commercialization of this important program.”.

“我们高度特异、口服活性的CDK2分子胶降解剂展示了令人信服的临床前特性，并有潜力改变乳腺癌患者及其他具有高度未满足医疗需求的肿瘤类型的治疗格局。我们很高兴与才华横溢的吉利德团队合作，加速这一重要项目的开发和商业化。”

Terms of the Agreement

协议条款

Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments. In addition, Kymera may also receive tiered royalties ranging from high single-digit to mid-teens on net product sales under the collaboration.

根据协议条款，Kymera 有资格获得总计高达 7.5 亿美元的付款，其中包括最高 8500 万美元的预付款和潜在的选择权行使付款。此外，Kymera 还可能根据合作下的净产品销售额获得从高个位数到十几百分比不等的分级特许权使用费。

Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option to exclusively license the program, Gilead will have global rights to develop, manufacture and commercialize all products resulting from the collaboration..

Kymera 将领导 CDK2 项目的所有研究活动。如果吉利德选择行使独家许可该计划的选项，吉利德将拥有合作产生的所有产品的全球开发、制造和商业化权利。

Gilead does not exclude acquired IPR&D expenses from its non-GAAP financial measures. This transaction with Kymera is expected to reduce Gilead’s GAAP and non-GAAP 2025 EPS by approximately $0.02 - $0.03.

吉利德并未将其获得的IPR&D费用排除在非GAAP财务指标之外。此次与Kymera的交易预计将会使吉利德2025年的GAAP和非GAAP每股收益减少约0.02至0.03美元。

About Gilead and Kite Oncology

关于吉利德和风筝肿瘤学

Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care.

吉利德和风筝肿瘤学公司正致力于改变癌症的治疗方法。我们正在通过下一代疗法、组合和技术进行创新，以期为癌症患者带来更好的治疗效果。我们正有目的地构建我们的肿瘤学产品组合和研发管线，以解决医疗领域最大的空白。

From antibody-drug conjugates and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer..

从抗体药物偶联物和小分子到基于细胞疗法的方法，我们正在为癌症患者创造新的可能性。

About Gilead Sciences

关于吉利德科学公司

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation.

吉利德科学公司是一家生物制药公司，三十多年来一直致力于医学领域的突破，旨在为全人类创造一个更健康的世界。公司专注于推进创新药物的研发，以预防和治疗危及生命的疾病，包括艾滋病、病毒性肝炎、新冠肺炎、癌症和炎症等。

Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif..

吉利德在全球35多个国家开展业务，总部位于加州福斯特城。

About Kymera Therapeutics

关于Kymera Therapeutics

Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics.

Kymera是一家处于临床阶段的生物技术公司，致力于开创靶向蛋白降解（TPD）领域，开发解决关键健康问题并有潜力显著改善患者生活的药物。Kymera正在利用TPD来应对传统疗法无法触及的疾病靶点和通路。

Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.

Kymera已将其首个降解剂推进至免疫疾病领域的临床阶段，目前正专注于构建一条行业领先的口服小分子降解剂管线，旨在为这些疾病的患者提供新一代便捷且高效的治疗方案。自2016年成立以来，Kymera连续多年被评为波士顿最佳工作场所之一。